Pertuzumab for the treatment of breast cancer

Cancer Investigation

Volumn 32, Issue 8, 2014, Pages 430-438

  Lynce, Filipa ^a   Swain, Sandra M ^a  

^a WASHINGTON CANCER INSTITUTE   (United States)

Author keywords

Breast cancer; Dimerization inhibitor; HER2 targeted therapy; Monoclonal antibody; Pertuzumab

Indexed keywords

BIOLOGICAL MARKER; CAPECITABINE; CARBOPLATIN; DOCETAXEL; GEMCITABINE; PERTUZUMAB; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CARDIOMYOPATHY; DIARRHEA; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; FEBRILE NEUTROPENIA; FETOTOXICITY; HUMAN; LEUKOPENIA; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; META ANALYSIS (TOPIC); MOLECULARLY TARGETED THERAPY; MUCOSA INFLAMMATION; MULTICENTER STUDY (TOPIC); MULTIMODALITY CANCER THERAPY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECOMMENDED DRUG DOSE; REVIEW; VOLUME OF DISTRIBUTION; VOLUME OF DISTRIBUTION AT STEADY-STATE; ANIMAL; BREAST NEOPLASMS; FEMALE; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; TREATMENT OUTCOME;

EID: 84907047380     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2014.922570     Document Type: Review

References (56)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182.
2. Seshadri R, Firgaira FA, Horsfall DJ,McCaul K, Setlur V, Kitchen P. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. J Clin Oncol 1993;11:1936-1942.
3. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus amonoclonal antibody against Her2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
4. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E,Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA,VogelVG,Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL,Klein PM, Ingle JN,WolmarkN. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-1684.
5. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, UntchM, SmithI,GianniL,Baselga J, Bell R, JackischC, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H,Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-1672.
6. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, Utriainen T, Kokko R, Hemminki A, Tarkkanen M, Turpeenniemi-Hujanen T, Jyrkkiö S, Flander M,Helle L, Ingalsuo S, Johansson K, Jääskeläinen AS, Pajunen M, Rauhala M, Kaleva-Kerola J, Salminen T, Leinonen M, Elomaa I, Isola J. FinHer Study Investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809-820.
7. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, PressM, Mackey J, Glaspy J, ChanA, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J; Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011;365:1273-1283.
8. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-2743.
9. Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM; CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012;366:109-119. ∗∗Initial report of the pivotal CLEOPATRA trial which led to the FDA approval of pertuzumab
10. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Diéras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K; EMILIA Study Group. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Eng J Med 2012;367:1783-1791.
11. Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, PoirierB,Morandi P, SemiglazovV, Srimuninnimit V, Bianchi G, Szado T, Ratnayake J, Ross G, Valagussa P. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomized multicentre, open-label, phase 2 trial. Lancet Oncol 2012;13:25-32. ∗∗Landmark study that supported the accelerated approval of pertuzumab by the FDA in the neoadjuvant setting
12. Scheeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, Tausch C, Seo JH, Tsai YF, Ratnayake J, McNally V, Ross G, Cortés J. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracyclinefree chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 2013;24(9):2278-2284.
13. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009;9:463-475.
14. Sundaresan S, Roberts PE, King KL, Sliwkowski MX, Mather JP. Biological response to ErbB ligands in nontransformed cell lines correlates with a specific pattern of receptor expression. Endocrinology 1998;139(12):4756-4764.
15. Yarden Y, Sliwkowski MX. Untangling the ErbB signaling network. Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-137.
16. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004;5:317-328
17. Chan R, Hardy WR, Laing MA, Hardy SE, Muller WJ. The catalytic activity of the ErbB-2 receptor tyrosine kinase is essencial for embryonic development. Mol Cell Biol 2002;22:1073-1078.
18. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors is a mediator of lateral signaling. EMBO J 1997;16:1647-1655.
19. Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 2009;69(24): 9330-9336.
20. AgusDB, Akita RW, FowWD, LewisGD, Higgins B, Pisacane PI, Lofgren JA, Tindell C, EvansDP, Maiese K, ScherHI, Sliwkowski MX. Targeting ligand activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002;2:127-137.
21. MullenP,CameronDA,HasmannM, SmythJF, LangdonSP. Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling.Mol CancerTher 2007;6:93-100.
22. Mendoza N, Philips GL, Silva J, Schwall R, Wickramasinghe D. Inhibition of ligand-mediated HER2 activation in androgenindependent prostate cancer. Cancer Res 2002;62:5485-5488.
23. Sakai K, Yokote H, Murakami-Murofushi K, Tamura T, Saijo N, Nishio K. Pertuzumab, a novel dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway. Cancer Sci 2007;98:1498-1503.
24. Mann M, Sheng H, Shao J, Williams CS, Pisacane PI, Sliwkowski MX, DuBois RN. Targeting cyclooxigenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology 2001;120:1713-1719.
25. Friess T, Bauer S, Burger AM, Fiebig H, Allison D, Muller H-J. In vivo activity of recombinant humanized monoclonal antibody 2C4 in xenografts is independent of tumor type and degree of HER2 overexpression [abstract no.496]. Eur J Cancer 2002;38(Supl 7):149.
26. Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, Hoeflich KP, Sliwkowski MX, Stern HM. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 2008;68(14):5878-5887
27. Nahta R, Hung MC, Esteva FJ. The HER2 targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 2004;64(7):2343-2346 ∗Original paper describing synergistic activity of trastuzumab with pertuzumab
28. Agus DB, Gordon MS, Taylor C, Natale RB, Karlan B, Mendelson DS, Press MF, Allison DE, Sliwkowski MX, Lieberman G, Kelsey SM, Fyfe G. Phase I Clinical Study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 2005;23:2534-2543.
29. Yamamoto N, Yamada Y, Fujiwara Y, Yamada K, Fujisaka Y, Shimizu T, Tamura T. Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (pertuzumab, RO4368451) in Japanese patients with solid tumors. Jpn J Clin Oncol 2009;39(4):260-266
30. Ng CM, Lum BL, Gimenez V, Kelsey S, Allison D. Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis. Pharm Res 2006;23(6):1275-1284.
31. Attard G, Kitzen J, Blagden SP, Fong PC, Pronk LC, Zhi J, Zugmaier G, Verweij J, de Bono JS, de Jonge M. A phase Ib study of pertuzumab, a recombinant humanized antibody to HER2, and docetaxel in patients with advanced solid tumours. Br J Cancer 2007;97(10):1338-13343.
32. Albanell J, Montagut C, Jones ET, Pronk L, Mellado B, Beech J, Gascon P, Zugmaier G, Brewster M, Saunders MP, Valle JW. A phase I study of the safety and pharmacokinetics of the combination of pertuzumab (rhuMab 2C4) and capecitabine in patients with advanced solid tumors. Clin Cancer Res 2008;14(9):2726-2731.
33. Portera CC, Walshe J, Rosing D, Walshe JM, Rosing DR, Denduluri N, Berman AW, Vatas U, Velarde M, Chow CK, Steinberg SM, Nguyen D, Yang SX, Swain SM. Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with trastuzumab-insenstive human epidermal growth factor receptor 2-positive metastatic breast cancer. Clin Cancer Res 2008;14:2710-2716.
34. Baselga J, Gelmon KA, Verma S, Wardley A, Conte P, Miles D, Bianchi G, Cortes J, McNallyVA, Ross GA, Fumoleau P,Gianni L. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor-2 positivemetastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010;28(7):1128-1144
35. Gianni L, Lladó A, Bianchi G, Lladó A, Bianchi G, Cortes J, Kellokumpu-Lehtinen PL, Cameron DA, Miles D, Salvagni S, Wardley A, Goeminne JC, Hersberger V, Baselga J. Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negativemetastatic breast cancer. J Clin Oncol 2010;28(7):1131-1137
36. Perez EA, Lopez-Vega JM, Mastro LD, Mastro DL, Petit T, Mitchell L, Pelizon CH, Andersson M. A combination of pertuzumab, trastuzumab and vinorelbine for first line treatment of patients with HER2-positive metastatic breast cancer: an open label, two cohort, phase II study (VELVET). 2012 ASCO Annual Meeting, J Clin Oncol 2012;30(Suppl):abstract TPS653.
37. Swain SM, Kim SB, Cortés J, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Knott A, Clark E, Ross G, Benyunes MC, Baselga J. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomized, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2013;14:461-471. ∗∗Second interim analysis of the CLEOPATRA trial confirming overall survival benefit with pertuzumab
38. Cortés J, Baselga J, Im YH, Im SA, Pivot X, Ross G, Clark E, Knott A, Swain SM. Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel inmetastatic breast cancer.AnnOncol 2013;24:2630-2635.
39. Miles D, Baselga J, Amadori D, Sunpaweravong P, Semiglazov V, Knott A, Clark E, Ross G, Swain SM. Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analysis form a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA). Breast Cancer Res Treat 2013;142:89-99
40. Garg A, Li J, Clark E, Knott A, Carrothers TJ, Marier JF, Cortés J, Brewster M, Visich J, Lum B. Exposure-response analysis of pertuzumab in HER2-positive metastatic breast cancer: absence of effect on QTc prolongation and other ECG parameters. Cancer Chemoth Pharmacol 2013;72:1133-1141.
41. Arandomizedmulticenter, double-blind, placebo controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy on patients with operable HER2-positive primary breast cancer. APHINITY trial. Available from ww.clinicaltrials.gov
42. Ellis PA, Barrios CH, Im Y, Patre M, Branle F, Perez EA. MARIANNE: a phase III, randomized study of trastuzumab-DM1 (T-DM1) with or without pertuzumab (P) compared with trastuzumab (H) plus taxane for first-line treatment of HER2-positive, progressive or recurrent locally advanced or metastatic breast cancer (MBC). ASCO Annual Meeting 2011. J Clin Oncol 2011;29 (Suppl):abstract TPS102.
43. Swain SM, Im Y, Im S-A, Miles D, Knott A, Clark E, Ross G, Baselga J. Safety of pertuzumab with trastuzumab and docetaxel in patients from Asia with HER2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA. AACR-SABCS. 2013; [P4-12-10].
44. DruckerAM,Wu S,Dang CT, Lacouture ME. Risk of rashwith the anti-HER2 dimerization antibody pertuzumab: a meta-analysis. Breast Cancer Res Treat 2012;135(2): 347-354.
45. U.S. Food and Drug Administration. Drug approval package, Perjeta (pertuzumab) injection. Available from: http://www. accessdata.fda.gov/drugsatfda docs/label/2013/125409s051lbl.pdf (accessed in February 2, 2014).
46. Swain SM, Ewer MS, Cortés J, Amadori D, Miles D, Knott A, Clark E, Benyunes MC, Ross G, Baselga J. Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in Cleopatra: a randomized, double-blind, placebo-controlled phase III study. The Oncologist 2013;18:257-264.
47. Gianni L, Bianchini G, Kiermaier A, Bianchi G, Im Y-H, Pienkowski T, Roman L, Liu M-C, Tseng L-M, Ratnayake J, Szado T, Ross GA, Valagussa P. Neoadjuvant pertuzumab (P) and trastuzumab (H): biomarker analysis of a 4-arm randomized phase II study (NeoSphere) in patients (pts) with HER2-positive breast cancer (BC). Cancer Res 2011;71(24 Suppl):Abstract nr S5-S1
48. Baselga J, Cortés J, Im S-A, Cortés J, Im S-A, Clark E, Kiermaier A, Ross G, and Swain SM. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in HER2-positive, first-line metastatic breast cancer (MBC). Cancer Res 2012;72(24 Suppl): Abstract nr S5-1
49. Makhija S, Amler LC, Glenn D, Ueland FR, Gold MA, Dizon DS, Paton V, Lin CY, Januario T, Ng K, Strauss A, Kelsey S, Sliwkowski MX, Matulonis U. Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J Clin Oncol 2010;28(7):1215-1223
50. Blumenthal GM, Scher NS, Cortazar P, Chattopadhyay S, Tang S, Song P, Liu Q, Ringgold K, Pilaro AM, Tilley A, King KE, GrahamL, Rellahan BL,WeinbergWC, Chi B,Thomas C, Hughes P, Ibrahim A, Justice R, Pazdur R. First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer. Clin Cancer Res 2013;19(18):4911-4916.
51. Perjeta. European Medicines Agency. Available from http://www. ema.europa.eu/docs/en GB/document library/EPAR Summary for the public/human/002547/WC500141071.pdf
52. Prowell T, Pazdur R. Pathological complete response and accelerated drug approval in early breast cancer. N Eng J Med 2012;366(26):2438-2441.
53. Cortazar P, Zhang L, Untch M,Mehta K, Costantino JP,Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Swain SM, Prowell T, Loibl S, Wickerham DL, Bogaerts J, Baselga J, Perou C, Blumenthal G, Blohmer J, Mamounas EP, Bergh J, Semiglazov V, Justice R, Eidtmann H, Paik S, Piccart M, Sridhara R, Fasching PA, Slaets L, Tang S, Gerber B, Geyer CE Jr, Pazdur R, Ditsch N, Rastogi P, EiermannW, vonMinckwitz G. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014, EarlyOnline Publication, 14 February 2014.
54. National Comprehensive Cancer Network guidelines Breast Cancer (Version 2014). http://www.nccn.org/professionals/ physician gls/pdf/breast.pdf. Accessed April 13, 2014
55. Phillips GDL, Fields CT, Li G, Dowbenko D, Schaefer G,Miller K, Andre F, Burris HA 3rd, Albain KS,Harbeck N, Dieras V, Crivellari D, Fang L, Guardino E, Olsen SR, Crocker LM, Sliwkowski MX. Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy. Clin Cancer Res 2014;20:456-468.
56. Bardia A, Baselga J. Neoadjuvant Therapy as a platform for drug development and approval in breast cancer. Clin Cancer Res 2013;19(23):6360-6370